Phase II study of nab‐paclitaxel + carboplatin for patients with non‐small‐cell lung cancer and inte...
Phase II study of nab‐paclitaxel + carboplatin for patients with non‐small‐cell lung cancer and interstitial lung disease
About this item
Full title
Author / Creator
Publisher
England: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
England: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
The prognosis of non‐small‐cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) is poor, and 5%‐20% of those receiving chemotherapy experience ILD exacerbation. To evaluate the safety and efficacy of nab‐paclitaxel plus carboplatin for NSCLC patients with ILD, we undertook a multicenter phase II study. Chemotherapy‐naïve patients...
Alternative Titles
Full title
Phase II study of nab‐paclitaxel + carboplatin for patients with non‐small‐cell lung cancer and interstitial lung disease
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6890441
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6890441
Other Identifiers
ISSN
1347-9032
E-ISSN
1349-7006
DOI
10.1111/cas.14217
